Author Archives:

QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals

Posted on by

QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals




QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals

The transaction provides liquidity option to existing investors and secures long-term capital to support continued growth.


RALEIGH, N.C.–(BUSINESS WIRE)–On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan.

The transaction was led by HarbourVest Partners, LLC (“HarbourVest”), with Pantheon Ventures, L.P. participating as a significant investor. Audax Strategic Capital (“ASC”) also participated through a separate structured growth investment. ASC also invested into the continuation vehicle as a syndicate investor.

The transaction offered the existing limited partners in the QHP selling fund the option to either capitalize on strong returns or roll their proceeds into the Continuation Vehicle (“CV”). There was strong participation from a broad set of limited partners, including existing limited partners of QHP. Other existing shareholders, including QHP’s subsequent fund, remain significant investors in Azurity and continue to support the company’s long-term strategy.

The new capital supports Azurity’s continued organic growth, business development and licensing, and potential strategic M&A. ASC provided additional acquisition capital to support the continued growth of Azurity.

Quotes:

“This CV reflects our strong conviction in Azurity’s strategy and leadership”, said Jeff Edwards, Partner at QHP. “We are pleased to partner with HarbourVest as lead investor alongside Pantheon and Audax Strategic Capital as well as other new investors, providing capital to support Azurity’s next phase of growth while offering liquidity to our existing LPs.”

“We are excited to continue our partnership with QHP and welcome our new investors as we enter the next phase of Azurity’s growth”, said Ronald Scarboro, CEO of Azurity. “This CV strengthens our ability to invest in our pipeline and expand our global reach while staying focused on delivering medicines to overlooked patients.”

“We are pleased to serve as the lead investor in the transaction which aligns with our strategy of partnering with what we believe are best-in-class general partners and their high performing portfolio companies,” said Nick Bellisario, Managing Director, HarbourVest Partners. “The QHP and Azurity teams have built an exceptional business, and we are excited to be investing alongside them in the company’s next chapter which will continue the mission of delivering innovative, high-quality medicine to overlooked patients.”

“Continuation vehicles are an increasingly important tool for high-quality assets, offering existing investors liquidity while providing new capital to support the next phase of growth,” said Kevin Dunwoodie, Partner at Pantheon. “Azurity has built a differentiated specialty pharmaceutical platform under QHP’s ownership, and we are pleased to partner with QHP, HarbourVest, Audax Strategic Capital and the management team to support the company’s continued development.”

Advisors

Goldman Sachs & Co. LLC (“GS”) acted as financial advisor to QHP, GS and Eaton Partners, a division of Stifel Nichols, both acted as placement agents, and Ropes & Gray, LLP acted as legal advisor on the transaction.

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Azurity’s medicines have benefited millions of people. For more information, visit www.azurity.com.

About QHP Capital

Based in the Research Triangle Park of North Carolina, QHP Capital invests in life sciences and pharma services companies with proven products, services, and enabling technologies, utilizing a strategic platform to source, diligence, and create value. Led by a senior team of investment, healthcare, and research professionals, and rooted in the legacy of Quintiles (now IQVIA) and NovaQuest, QHP seeks to partner with founders and management teams to create long-term value. QHP Capital is the management company for NovaQuest Private Equity. For more information, please visit www.qhpcapital.com.

About HarbourVest Partners

HarbourVest is an independent, global private markets firm with over 43 years of experience and more than $146 billion of assets under management as of June 30, 2025. Our interwoven platform provides clients access to global primary funds, secondary transactions, direct co-investments, real assets and infrastructure, and private credit. Our strengths extend across strategies, enabled by our team of more than 1,250 employees, including more than 235 investment professionals across Asia, Europe, and the Americas. Across our private markets platform, our team has committed more than $63 billion to newly formed funds, completed over $64 billion in secondary purchases, and invested over $47 billion in direct operating companies. We partner strategically and plan our offerings innovatively to provide our clients with access, insight, and global opportunities.

About Pantheon

Pantheon has been at the forefront of private markets investing for more than 40 years, earning a reputation for providing innovative solutions covering the full lifecycle of investments, from primary fund commitments to co-investments and secondary purchases, across private equity, private credit, and real assets. For more information, please visit www.pantheon.com.

We have partnered globally with institutional investors of all sizes as well as a growing number of private wealth advisers and investors, with approximately $85bn in discretionary assets under management (as of September 30, 2025).

Leveraging our specialized experience and global team of professionals across Europe, the Americas, and Asia, we invest with purpose and lead with expertise to build secure financial futures.

For further information, please contact:

Pantheon

Mariella Reason, Pantheon Communications

Tel: +44 20 3473 3975 | Email: mariella.reason@pantheon.com

About Audax Strategic Capital

Based in New York and London, Audax Strategic Capital is a flexible partner to private equity sponsors seeking customized equity solutions to drive the continued growth of their portfolio companies. ASC is part of the Audax Private Equity platform, a capital partner to middle market companies with $19.5 billion of assets under management, as of January 2026, over 300 employees, and 100-plus investment professionals. For more information, visit www.AudaxStrategicCapital.com or follow ASC on LinkedIn.

Contacts

Media Contact
Silvia Cruz

silvia.cruz@qhpcapital.com

Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable

Posted on by

Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable




Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable

Blume Ventures leads seed round; Company completes 500 person beta




SAN FRANCISCO–(BUSINESS WIRE)–Mave Health, a neurotech company, announced $2.1 million in seed funding led by Blume Ventures with participation from other funds and angel investors, including Stanford Angels, Dhaval Shroff, and Raymond Russell. The company recently launched a non-invasive wearable headset built to improve focus, elevate mood, and regulate stress in just 20 minutes a day.

Mave debuted with over 500 beta customers ahead of its public release last month. Based on self-reported data collected after four weeks of use:

  • 80% reported productivity gains exceeding 60%
  • Users reported an average mood improvement of 77%
  • 75% reported stress reductions above 50%

The wearable headset supports everyday mental health and cognitive performance. Its underlying technology, transcranial direct current stimulation (tDCS), has been studied for over 25 years, with more than 10,000 published papers globally. tDCS has an excellent safety profile and is well-suited for at-home use. Mave packages this science into a lightweight, consumer-friendly device.

“The brain is the most complex system we rely on every day, and modern life is constantly overloading it. We expect it to perform at peak levels without giving it the support it needs,” said Dhawal Jain, Co-founder and CEO of Mave Health. “Instead of chasing short-term boosts that come with long-term costs, we believe in strengthening the underlying systems that drive focus, mood, and stress regulation. Our approach is to use neurotechnology that is proven to be safe, effective, and easy to use.”

About the Product

The Mave headset delivers low-intensity electrical stimulation designed to strengthen the prefrontal cortex, the brain region associated with attention, emotional regulation, and stress response. Users wear the device for 20 minutes a day while working, reading, meditating, or going about their routine. There is no learning curve and no active effort required.

Most users report noticeable improvements within 15 to 20 days, with benefits compounding over time. The companion app allows users to log sessions, personalize protocols, and track progress without collecting any brain data.

Availability

Mave is available for pre-order at $495 and requires no subscription fees. Shipping begins in April 2026 to customers in the United States and India.

Technical Specifications

The Mave headset weighs 100 grams and lasts up to one month on a single charge with regular use. Each stimulation session lasts 20 minutes and uses an intensity of 1-2 mA, targeting the prefrontal cortex.

The headset does not collect brain data or require ongoing internet connectivity. The companion app can sync with popular fitness wearables to help users track correlations with sleep quality, heart rate variability, resting heart rate, and other related metrics.

Company Vision

“Most of us only think about mental health when something goes wrong,” said Dhawal Jain, Co-founder and CEO of Mave Health. “That is why my co-founders Jai Sharma, Aman Kumar, and I started Mave. We are giving people the ability to regain control over their focus, energy, and clarity so they can perform at their best and live more fully every day.”

About Mave Health

Mave Health exists to unlock the productivity and resilience that modern life often keeps out of reach. The company develops non-invasive wearable headsets to help people improve focus, mood and stress regulation. The product uses transcranial direct current stimulation (tDCS) to strengthen the prefrontal cortex in 20-minute daily sessions. Mave Health is a San Francisco and Bengaluru-based neurotechnology company founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar.

Contacts

Media Contact and Assets
Emily O’Brien, emily@emilyobrienconsulting.com
Press folder images and videos

Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift

Posted on by

Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift




Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift

NEW YORK–(BUSINESS WIRE)–Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity – from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign.


The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut across the sector in 2024–2025, unprecedented policy uncertainty, accelerating AI adoption, and intensifying portfolio pressure, organizations must transform all functions simultaneously, not sequentially, to remain competitive.

A Proven Leader Across Transactions and Transformations

Stacey Petrey brings more than 25 years of experience and a track record spanning more than 75 completed transactions. Stacey served as a Partner in PwC’s Deals practice where she focused on integrations, separations, value creation, and change management. Prior to PwC, she held senior business, finance, and HR leadership roles at Bausch Health, Mylan (Viatris), Perrigo, Fidelity Investments, PerkinElmer, and Credit Suisse First Boston. She holds a doctorate from the University of Pennsylvania, a master’s from Cornell University, and a bachelor’s from Penn State University, and is a published thought leader on AI’s impact on biopharma organizational design and workforce architecture.

Four Integrated Capabilities

The People and Organization Practice operates across four service lines:

  • Transformations & Transactions: Day 1 operating model design, synergy assessment, pre- and post-close integration and separation support, and change management
  • Organization Design & Workflow Excellence: Best Practice Organization benchmarking, operating model design, organizational structure, role and decision rights redesign, AI use case prioritization, and governance
  • Talent, Rewards & Performance Strategy: Career architecture, capability models, incentive compensation design, succession planning, and retention strategy
  • Learning & Leadership Development: Salience Learning, learning strategy, leadership development, capability building, and measurement frameworks

The practice draws on Blue Matter’s deep functional expertise across Commercial, Medical Affairs, R&D, Market Access, and Enterprise Learning to deliver cross-functional solutions that work in practice, not just in theory.

According to Petrey, “Biopharma organizations must transform all functions at once, not sequentially, while keeping the portfolio pipeline moving and talent in place. That requires a partner who understands the science of the business, the deal dynamics, the incentive structures, and the human dynamics of change. That is what this practice is built to deliver.”

George Schmidt, Head of Consulting at Blue Matter, added, “We’ve spent years building deep expertise in how biopharma organizations operate. Stacey brings transactions and transformation experience to activate that expertise at scale, integrating organizational design, talent strategy, and learning into a single, connected offering. It is a meaningful step forward for our clients.”

About Blue Matter

Blue Matter (www.bluematterconsulting.com) is a global commercialization partner serving the life sciences industry. Operating from offices across North America, Europe, and Asia, Blue Matter serves a broad spectrum of biopharmaceutical organizations, from top-20 global companies to emerging biotech firms. The firm helps clients maximize value at the product, portfolio, and organization levels through market insights, strategic and operational consulting, and communications services.

Contacts

Media Contact
Craig Dunkley, Chief Marketing Officer

cdunkley@bluematterconsulting.com
+1 919 539 0658

Tiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk Exosomes

Posted on by

Tiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk Exosomes




Tiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk Exosomes

Strategic US-EU alliance combines high-yield mAb production with industrial-scale exosome loading to eliminate the need for biologics by injection

ROANOKE, Va. & LIÈGE, Belgium–(BUSINESS WIRE)–The Tiny Cargo Company (“Tiny Cargo”) and Bio-Sourcing SA (‘Bio-Sourcing’) today announced a strategic partnership to develop an innovative oral delivery platform for monoclonal antibodies (mAbs). The collaboration utilizes goat-milk extracellular vesicles (EVs), specifically exosomes, to create a new class of shelf-stable, patient-friendly biologics.




The collaboration unites two proprietary technological breakthroughs:

  • Tiny Cargo’s world-first, cGMP-compliant industrial platform built to isolate, purify, and load milk-derived exosomes with complex therapeutic payloads.
  • Bio-Sourcing’s large-scale platform for producing high-potency mAbs and EVs directly in goat milk offers major cost savings and scalability benefits compared to traditional bioreactors.

While monoclonal antibodies are essential to modern medicine, their vulnerability to gastrointestinal breakdown has historically required delivery via injection or infusion. Milk-derived exosomes are evolutionarily designed to withstand the gut environment and transport molecular cargo into the bloodstream. By incorporating Bio-Sourcing-derived antibodies into these natural nanovesicles, the partners aim to eliminate the “needle barrier” altogether.

“By pairing Bio-Sourcing’s high-yield, sustainable production with Tiny Cargo’s sophisticated isolation and loading capabilities, we are positioned to unlock the ‘holy grail’ of biologics: true oral delivery,” said Bertrand Mérot, Founder and CEO of Bio-Sourcing SA. “This alliance not only advances our technical roadmap but strengthens our footprint in the U.S. market through a powerful transatlantic synergy.”

Bio-Sourcing’s platform uses a specific goat breed to produce mAbs at a lower cost than traditional methods. At the same time, Tiny Cargo’s unique purification techniques ensure these therapies meet pharmaceutical-grade standards for clinical use.

“Milk-derived exosomes are among the most resilient delivery systems in nature,” said Alan Gourdie, CEO of The Tiny Cargo Company. “The ability to source both the antibody and the delivery vehicle from the same biological starting point is a rare and powerful advantage. For the hundreds of millions of patients currently reliant on injectable mAbs, transitioning to an oral format would fundamentally transform how biologics are prescribed, distributed, and accessed globally.”

The joint venture will initially focus on assessing therapeutic applications and oral bioavailability. Currently, there are no FDA or EMA-approved oral mAbs, making this alliance a leader in pharmaceutical innovation.

About The Tiny Cargo Company

The Tiny Cargo Company, headquartered in Roanoke, Virginia, USA, is a biotechnology company pioneering the industrial-scale production of highly purified milk-derived exosomes. The company has developed proprietary technologies for isolating, purifying and loading exosomes with therapeutic and cosmetic cargoes, enabling applications across pharmaceuticals, nutraceuticals and advanced skincare.

Tiny Cargo’s world-first cGMP-ready manufacturing platform enables scalable production of exosome-based delivery systems for peptides, monoclonal antibodies, expression constructs and other biologics. The company’s platform is designed to integrate with multiple biologic production systems, allowing therapeutic molecules from diverse sources to be paired with milk-derived exosomes for advanced delivery applications.

Tiny Cargo is welcoming contacts and partnership enquiries via LinkedIn.

www.tinycargo.com

About Bio‑Sourcing

Bio‑Sourcing is developing a sustainable, scalable platform to produce biotherapeutics, including monoclonal antibodies in the milk – comprising EVs – of a particular breed of goats, creating industrial volumes at a drastically lower cost and capital expenditure versus conventional cell‑bioreactor systems. The platform supports both injectable and oral delivery formats. Building on the leadership of two international consortia, Bio‑Sourcing has twice been recognized by the European Union with competitive Eurostars funding; in 2024 it led a consortium to develop an oral adalimumab, and in 2026 alongside an EU partner, it was granted funding to advance an oral anti‑HER2 trastuzumab—reinforcing its position at the forefront of the oral delivery of mAbs.

Bio-Sourcing will be attending the Bio Europe Spring Conference and LSX in Lisbon, Portugal, on March 25 and 26, 2026, and is welcoming contacts via LinkedIn.

www.bio-sourcing.com| Bio-Sourcing – One pager | Trastuzumab (Eurostars 2026) |Nature research

Contacts

Keith Bowermaster, Mighty Spark Communications

k.bowermaster@mightysparkcommunications.com

Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design

Posted on by

Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design




Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design

BERKELEY, Calif.–(BUSINESS WIRE)–The Open Molecular Software Foundation (OMSF) today announced a new research fellowship between the OpenFold Consortium and the University of Washington Institute for Protein Design (IPD). Nobel Laureate David Baker is the Director of the IPD, a professor of biochemistry, and HHMI Investigator at UW Medicine. This fellowship is aimed at accelerating the development of open-source artificial intelligence tools for protein structure prediction and design ultimately to be used for new drug discovery.


The fellowship will support graduate students and postdoctoral scholars in the Baker Lab. With funding from the OpenFold Consortium fellows will focus on creating new state-of-the-art AI models for antibody-antigen design and structure prediction. Following an approach shared by OpenFold and the IPD, all resulting code from this collaboration will be released under permissive licenses for use by researchers and companies worldwide.

“The AI revolution in biology is built on a foundation of openness — researchers sharing data, code, and ideas freely so that others can build on them,” said Baker. “We’re excited to continue this tradition with OpenFold.”

“This collaboration with the Baker Lab marks a defining moment for open biomolecular AI,” said Dr. Woody Sherman, Chair of the OpenFold Consortium Executive Committee and Chief Innovation Officer at PsiThera. “This collaboration brings extraordinary depth across protein design, structure prediction, and large-scale experimental data generation. By building these capabilities as open, shared infrastructure, OpenFold is laying the foundation for a new era of biological discovery where AI models become community resources that accelerate innovation, enable entirely new classes of therapeutics, and deliver impact far beyond what any single organization could achieve.”

As part of this collaboration, the Baker Lab will conduct AI model development. To enhance the longevity and ease-of-use of new software, OpenFold engineers will provide technical support for packaging, documentation, and maintenance. All finished models developed with OMSF fellowship support will be shared publicly under permissive licenses.

About OMSF and OpenFold

The Open Molecular Software Foundation is a nonprofit 501(c)(3) organization supporting open, community-driven molecular software. The OpenFold project within OMSF advances open biomolecular AI by enabling shared infrastructure, evaluation, and community resources to accelerate scientific progress. OMSF is modeled after open source consortia in software technology such as the Linux Foundation.

The OpenFold Consortium is supported by a growing community of academic, industry, and philanthropic partners committed to building open scientific infrastructure for the next era of biology. OpenFold welcomes mission-aligned supporters interested in accelerating open innovation in biomolecular AI and drug discovery.

About the UW Institute for Protein Design

The Institute for Protein Design at the University of Washington creates new molecules that solve challenges in medicine, technology, and sustainability. Founded in 2012 by Nobel laureate David Baker, the Institute unites and trains experts in AI, biochemistry, medicine, and other disciplines. The IPD is building proteins to improve health, prevent pandemics, eliminate pollution, and organize matter at the atomic scale.

Contacts

Media Contact:

Mallory R. Tollefson, Ph. D.

Business Development and Project Manager

mallory.tollefson@omsf.io
https://openfold.io/

LiveWorld Reports 2025 Financial Results

Posted on by

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

  • Total twelve-month revenues of $11.1 million
  • Healthcare revenues of $10 million in 2025
  • Net income from operations of $326,000
  • Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

LIVEWORLD, INC.
UNAUDITED CONDENSED BALANCE SHEETS
(In thousands, except share data)
       
  December 31,   December 31,
    2025       2024  
ASSETS      
Current assets      
Cash and cash equivalent $ 7,313     $ 6,603  
Accounts receivable, net   1,309       682  
Prepaid expenses   246       290  
Total current assets   8,868       7,575  
       
Property and equipment, net   18       33  
Other assets   27       27  
Total assets $ 8,913     $ 7,635  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities      
Accounts payable $ 242     $ 182  
Accrued employee expenses   595       1,068  
Other accrued liabilities   1,555       413  
Deferred revenue   761       860  
Total current liabilities   3,153       2,523  
Total liabilities   3,153       2,523  
       
Stockholders’ equity      
  Common stock: $0.001 par value, 100,000,000 shares authorized
45,633,442 issued and outstanding as of December 31, 2025, and
December 31, 2024, respectively		   34       34  
Additional paid-in capital   144,773       144,451  
Accumulated deficit   (139,047 )     (139,373 )
Total stockholders’ equity   5,760       5,112  
Total liabilities and stockholders’ equity $ 8,913     $ 7,635  
               

LIVEWORLD, INC.
CONDENSED STATEMENT OF OPERATIONS
(In thousands, except per share data)
       
  Twelve Months Ended
December 31,
    2025     2024
Total revenues $ 11,140   $ 11,348
Cost of revenues                  5,404                 6,023
Gross Margin                  5,736                 5,325
Operating Expense      
Product development                  1,336               1,048
Sales and marketing                  1,630               1,554
General and administrative                  2,504     2,634
Total operating expense                  5,470     5,236
Income from operations                     266     89
Income before tax                     266     89
Other Income                       88     5
Provision for income taxes                       28     25
Net income from operations                     326     69
       
Earnings per share analysis from operations:      
Basic income per share $ 0.01   $ 0.00
Shares used in computing basic loss per share   45,633,442     45,633,442
Diluted net income (loss) per share $ 0.01   $ 0.00
Shares used in computing diluted income (loss) per share   54,992,049     56,350,862
       
       
Departmental allocation of stock-based compensation:      
Cost of revenues $ 81   $ 80
Product development   21     18
Sales and marketing   31     33
General and administrative   188     189
Total stock-based compensation $ 321   $ 320
           

LIVEWORLD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
  Twelve Months Ended
December 31,
    2025       2024  
Cash flows from operating activities:      
Net income (loss) $ 326     $ 69  
Adjustments to reconcile net income (loss) provided by (used in) operating activities:    
Depreciation of long-lived assets   21       26  
Stock-based compensation   321       320  
Changes in operating assets and liabilities:      
Accounts receivable   (627 )     1,019  
Other assets   47       (66 )
Accounts payable   60       (56 )
Accrued liabilities   668       249  
Deferred revenue   (100 )     422  
Net cash provided by (used in) operating activities   716       1,983  
Cash flows from investing activities:      
Purchase of property and equipment   (6 )     (15 )
Net cash provided by (used in) investing activities   (6 )     (15 )
Cash flows from financing activities:      
Proceeds from exercise of stock options   —–       —-  
Net cash provided by (used for) financing activities   —–       —-  
Change in cash and cash equivalent   710       1,968  
Cash and cash equivalents, beginning of period   6,603       4,635  
Cash and cash equivalents, end of period $ 7,313     $ 6,603  
       
Supplemental disclosure of non-cash financing and investing activities:    
Income tax paid $ 28     $ 25  

LiveWorld Reports 2025 Financial Results

Posted on by

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

  • Total twelve-month revenues of $11.1 million
  • Healthcare revenues of $10 million in 2025
  • Net income from operations of $326,000
  • Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

LIVEWORLD, INC.
UNAUDITED CONDENSED BALANCE SHEETS
(In thousands, except share data)
       
  December 31,   December 31,
    2025       2024  
ASSETS      
Current assets      
Cash and cash equivalent $ 7,313     $ 6,603  
Accounts receivable, net   1,309       682  
Prepaid expenses   246       290  
Total current assets   8,868       7,575  
       
Property and equipment, net   18       33  
Other assets   27       27  
Total assets $ 8,913     $ 7,635  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities      
Accounts payable $ 242     $ 182  
Accrued employee expenses   595       1,068  
Other accrued liabilities   1,555       413  
Deferred revenue   761       860  
Total current liabilities   3,153       2,523  
Total liabilities   3,153       2,523  
       
Stockholders’ equity      
  Common stock: $0.001 par value, 100,000,000 shares authorized
45,633,442 issued and outstanding as of December 31, 2025, and
December 31, 2024, respectively		   34       34  
Additional paid-in capital   144,773       144,451  
Accumulated deficit   (139,047 )     (139,373 )
Total stockholders’ equity   5,760       5,112  
Total liabilities and stockholders’ equity $ 8,913     $ 7,635  
               

LIVEWORLD, INC.
CONDENSED STATEMENT OF OPERATIONS
(In thousands, except per share data)
       
  Twelve Months Ended
December 31,
    2025     2024
Total revenues $ 11,140   $ 11,348
Cost of revenues                  5,404                 6,023
Gross Margin                  5,736                 5,325
Operating Expense      
Product development                  1,336               1,048
Sales and marketing                  1,630               1,554
General and administrative                  2,504     2,634
Total operating expense                  5,470     5,236
Income from operations                     266     89
Income before tax                     266     89
Other Income                       88     5
Provision for income taxes                       28     25
Net income from operations                     326     69
       
Earnings per share analysis from operations:      
Basic income per share $ 0.01   $ 0.00
Shares used in computing basic loss per share   45,633,442     45,633,442
Diluted net income (loss) per share $ 0.01   $ 0.00
Shares used in computing diluted income (loss) per share   54,992,049     56,350,862
       
       
Departmental allocation of stock-based compensation:      
Cost of revenues $ 81   $ 80
Product development   21     18
Sales and marketing   31     33
General and administrative   188     189
Total stock-based compensation $ 321   $ 320
           

LIVEWORLD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
  Twelve Months Ended
December 31,
    2025       2024  
Cash flows from operating activities:      
Net income (loss) $ 326     $ 69  
Adjustments to reconcile net income (loss) provided by (used in) operating activities:    
Depreciation of long-lived assets   21       26  
Stock-based compensation   321       320  
Changes in operating assets and liabilities:      
Accounts receivable   (627 )     1,019  
Other assets   47       (66 )
Accounts payable   60       (56 )
Accrued liabilities   668       249  
Deferred revenue   (100 )     422  
Net cash provided by (used in) operating activities   716       1,983  
Cash flows from investing activities:      
Purchase of property and equipment   (6 )     (15 )
Net cash provided by (used in) investing activities   (6 )     (15 )
Cash flows from financing activities:      
Proceeds from exercise of stock options   —–       —-  
Net cash provided by (used for) financing activities   —–       —-  
Change in cash and cash equivalent   710       1,968  
Cash and cash equivalents, beginning of period   6,603       4,635  
Cash and cash equivalents, end of period $ 7,313     $ 6,603  
       
Supplemental disclosure of non-cash financing and investing activities:    
Income tax paid $ 28     $ 25  

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Posted on by

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors




Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.

“As we continue advancing innovative solutions in women’s health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “His experience evaluating and advising biotechnology and medical device companies adds an important strategic perspective to our Board, and we are thrilled to welcome him at this important stage in the Company’s growth.”

Dr. Eichenbaum commented, “Femasys is advancing innovative, non-surgical solutions designed to improve the patient experience while reducing cost and complexity in women’s reproductive care. I look forward to working with the Board and management team to support the Company’s continued growth and innovation.”

The Company also expresses its appreciation to Joshua Silverman for his service on the Board of Directors. His capital markets perspective and strategic counsel supported Femasys during a period of important growth and development.

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1

FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Posted on by

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting




Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Selected for oral presentation at Clinical Trials Mini Symposium

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.

The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.

Oral Presentation

Title: First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: CTMS01: Updates in Anticancer Immunotherapies
Date: Saturday, April 18, 2026
Presentation Time: 10:21 a.m. – 10:31 a.m. Pacific Time
Location: Ballroom 6A – Upper Level – San Diego Convention Center

Oncology Program

PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Posted on by

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate




Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

  • AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry

TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) — Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”). The engagement will deploy Kala Bio’s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Kala’s Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and under private cloud LLM infrastructure (supplied by Kala), Red Light intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through its clinical development program.

PEX010 is Filament’s patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others. These indications represent areas of growing clinical and commercial momentum, with programs from Compass Pathways and AtaiBeckley also advancing psilocybin and psychedelic candidates toward late-stage regulatory milestones, and Johnson & Johnson’s Spravato continuing to demonstrate strong commercial traction in treatment-resistant depression.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with exclusive worldwide distribution/development license owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical R&D workflows. The platform enables autonomous research loops capable of generating, simulating, and optimizing study scenarios at scale — compressing timelines and expanding the number of viable options considered before execution. The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development, an area where NVIDIA and Eli Lilly have also committed significant resources through dedicated computing partnerships and in-house platforms.

Management Commentary

“As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. “PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world. By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010’s extensive clinical program.”

“Filament’s focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,” said Ben Lightburn, Chief Executive Officer of Filament Health Corp. “With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio’s Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve.”

“Red Light’s decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address,” said Avi Minkowitz, Chief Executive Officer of Kala Bio. “Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference. We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”

About Researgency.ai

Researgency.ai is an agentic AI platform under worldwide distribution/development license by Kala Bio Inc. (NASDAQ: KALA) launched by Younet.ai, designed to bring autonomous research-agent workflows to biotechnology R&D planning. The platform deploys purpose-built AI agents that can simulate scenarios, optimize protocols, and support evidence-driven decisions in a secure, on-premises environment built for pharmaceutical-grade compliance. For more information, visit www.Researgency.ai.

About PEX010

PEX010 is a patented botanical psilocybin drug candidate developed by Filament Health Corp. PEX010 is formulated as a capsule for oral administration and is protected by Filament’s portfolio of 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations. PEX010 is currently supplied to more than 70 clinical research sites worldwide and is being studied in multiple Health Canada and FDA-authorized clinical trials across a range of mental health indications.

About Red Light Holland

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. The Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws. Red Light has entered into a definitive arrangement agreement to acquire Filament Health Corp., which is expected to expand the Company’s drug development platform with GMP manufacturing capabilities, comprehensive Health Canada licensing, FDA-authorized clinical programs, and a portfolio of 76 issued patents. For more information, visit www.RedLight.co.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates. 

About Kala Bio, Inc.

Kala Bio, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry. For more information, visit www.kalarx.com.

For additional information on Red Light Holland:

Todd Shapiro 
Chief Executive Officer & Director 
Tel: 647-204-7129 
Email: todd@redlight.co 
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director 
Email: ben@filament.health
Website: www.filament.health

For additional information on Kala Bio, Inc.:

Kala Bio, Inc.
Avi Minkowitz
Chief Executive Officer
Email: am@kalarx.com
Website: www.kalarx.com
www.Researgency.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian and United States securities legislation, including statements regarding the expected benefits and applications of the Researgency.ai platform in connection with PEX010 and Red Light’s drug development programs; the anticipated impact of AI-driven research tools on clinical development timelines and decision-making; the expected completion of Red Light’s acquisition of Filament; and the future development and commercialization of PEX010. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the ability to develop, deploy, and integrate new AI technologies; the performance and reliability of AI models and simulations; data availability and quality; cybersecurity and privacy considerations; the regulatory environment for psychedelic substances and AI-driven tools in Canada, the United States, and internationally; the ability to complete the acquisition of Filament on the anticipated terms and timeline; the ability to realize the anticipated benefits of the Filament transaction; the ability to retain key personnel; risks inherent in clinical drug development; and other risks described in Red Light’s and Kala Bio’s respective public filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neither Red Light nor Kala Bio undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.